We’re in the midst of a paradigm shift in biomarker science. Once considered exploratory, biomarker signatures have evolved into strategic assets - tools that actively de-risk decision-making across ...

BostonGene has entered a new collaboration with AstraZeneca to apply its foundation AI model to oncology drug development, aiming to improve early trial decision-making around safety, efficacy, and ...

Background: The Prognostic Lung Fibrosis Consortium (PROLIFIC) was formed to develop well-qualified assays suitable for use as prognostic biomarkers within the context of clinical trials for Idiopathic ...

Ibex’s high-performance AI platform—already deployed across more than 50 health systems worldwide and used in collaboration ...

Extending their collaboration, Genialis and Debiopharm continue working towards a patient classifier to support WEE1 clinical development BOSTON--(BUSINESS WIRE)-- Genialis, the RNA biomarker company, ...

Researchers from Critical Path Institute's ® (C-Path) Predictive Safety Testing Consortium have proposed glutamate dehydrogenase (GLDH) as a more liver-specific biomarker for detecting liver injury, ...

Cancer biomarkers span a broad biological spectrum, including proteins, metabolites, and nucleic acids detectable in samples such as tissue biopsies and blood. 1 At the beginning of a biomarker ...

GENT, Belgium & FREMONT, Calif.--(BUSINESS WIRE)--ADx NeuroSciences, a wholly owned subsidiary of Fujirebio and a leader in neurodegenerative disease biomarker development, and Alamar Biosciences, a ...

Digital biomarker to enhance precision, reduce patient burden and boost efficiency of global Phase 2 trial of NEU-411 in early Parkinson’s disease SOUTH SAN FRANCISCO, Calif.--(BUSINESS ...

MINNEAPOLIS, Nov. 5, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the release of clinically relevant spatial biology data. The data was generated using Bio-Techne's ...

Two biomarker tests -- one for blood and the other for stool -- are mainstays in the treatment of inflammatory bowel disease (IBD), but gastroenterologists are hoping to gain even more insight from ...

The Phase 1b trial consisted of 24 patients with Parkinson’s disease, who received twice-weekly dosing of either HER-096 or placebo over a four-week period. The trial’s exploratory biomarker program ...